Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcific tendinopathy of the direct head of rectus femoris: a rare cause of groin pain treated with ultrasound guided percutaneous irrigation.

Journal of ultrasound·2019
Same author

Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.

The bone & joint journal·2018
Same author

Dexamethasone-related adrenal insufficiency in patients with brain and skull base tumours.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2018
Same author

Author Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study.

British journal of cancer·2018
Same author

Longer duration of symptoms at the time of presentation is not associated with worse survival in primary bone sarcoma.

The bone & joint journal·2018
Same author

The role of grade in local recurrence and the disease-specific survival in chondrosarcomas.

The bone & joint journal·2018
Same journal

Oral Etoposide for Relapsed or Refractory Ewing Sarcoma in Adolescent and Adult Patients.

Sarcoma·2024
Same journal

Incidence of Undifferentiated Pleomorphic Sarcoma (UPS) in the United States.

Sarcoma·2024
Same journal

Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients.

Sarcoma·2024
Same journal

ATRX and Its Prognostic Significance in Soft Tissue Sarcoma.

Sarcoma·2024
Same journal

Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum.

Sarcoma·2024
Same journal

Exploring the Diagnostic Dilemma of Indeterminate Pulmonary Nodules in Patients with Primary Sarcoma of Bone.

Sarcoma·2024
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Paget's Osteosarcoma - no Cure in Sight.

P J Shaylor1, D Peake, R J Grimer

  • 1The Royal Orthopaedic Hospital Oncology Service Bristol Road South Birmingham B 31 2AP UK.

Sarcoma
|June 4, 2008
PubMed
Summary
This summary is machine-generated.

Sarcoma developing in Paget's bone disease has a poor prognosis, with no 5-year survivors in this study despite modern treatments. Limb salvage and amputation showed similar outcomes, indicating this condition remains largely incurable.

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Related Experiment Videos

Last Updated: Jul 4, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Area of Science:

  • Orthopaedic Oncology
  • Bone Sarcomas
  • Paget's Disease of Bone

Background:

  • Sarcomatous change in Paget's disease is a rare but serious complication.
  • It predominantly affects patients over 40 years of age.
  • Historically, survival rates for this condition are very low.

Purpose of the Study:

  • To evaluate survival outcomes for patients with Paget's osteosarcoma.
  • To assess the efficacy of modern staging and limb salvage techniques.
  • To determine if outcomes have improved compared to historical data.

Main Methods:

  • Retrospective review of 26 patients diagnosed with sarcoma secondary to Paget's disease.
  • Data collected from the Royal Orthopaedic Hospital Oncological database.
  • Analysis included comparison of limb salvage versus amputation outcomes.

Main Results:

  • No patients survived beyond 5 years; 1-year survival was 53%, and 2-year survival was 25%.
  • Median survival was 21 months for curative intent and 7 months for palliative treatment.
  • Limb salvage surgery resulted in local recurrence in 4 out of 5 patients, with no survival benefit over amputation.

Conclusions:

  • Sarcomatous change in Paget's disease carries an appalling prognosis and remains largely incurable.
  • Modern management techniques have not improved survival rates.
  • Limb salvage and ablation offer similar poor prognoses, and neither is currently recommended.